From the many somatic mutations identified by whole-exome analysis, we focused on two inactivating mutations affecting SMARCA4 and CDKN2A to investigate the efficacy of EZH1/2 and CDK4/6 inhibitors as candidate therapeutic options for the treatment of TCS patients. This evidence concerns the gene SMARCA4 and Treacher-Collins syndrome.